Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sino Biopharmaceutical ( (HK:1177) ) has issued an update.
Sino Biopharmaceutical Limited has announced the successful enrollment of the first patient in a Phase I clinical trial for LM-2417, a NaPi2b/4-1BB bispecific antibody, marking a significant step in its clinical development. This innovative therapy, developed by LaNova Medicines, targets NaPi2b, a promising anti-tumor target, and aims to enhance anti-tumor effects while minimizing toxicity. The trial will evaluate the safety and efficacy of LM-2417 as a monotherapy or in combination with other drugs, potentially positioning it as a First-in-Class immunotherapy.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$9.80 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company in the pharmaceutical industry, focusing on the development of innovative drugs. Its primary products include therapeutic drugs for various cancers, and it operates with a market focus on developing novel treatments through its subsidiaries, such as LaNova Medicines Limited.
Average Trading Volume: 174,128,176
Technical Sentiment Signal: Buy
Current Market Cap: HK$152.4B
For an in-depth examination of 1177 stock, go to TipRanks’ Overview page.